Ulcerative Colitis: Symptoms, Diagnosis, and Treatment Step by Step

Ulcerative colitis (UC) is a chronic, immune-mediated inflammatory bowel disease in which the immune system attacks the lining of the colon and rectum. Unlike Crohn's disease, which we cover in a separate article, inflammation in UC is limited to the mucosal layer (rather than the full thickness of the bowel wall) and always begins in the rectum, spreading in a continuous band toward the more proximal parts of the colon — it never appears as isolated, skipping patches the way Crohn's disease does.

The disease affects anywhere from several dozen to over a hundred people per 100,000 population in industrialized countries, with a peak onset most often between ages 15 and 30, though diagnosis is sometimes made later. The exact cause is unknown — the leading model combines a genetic predisposition, an abnormal immune response to one's own gut microbiome, and environmental factors, including diet and prior gastrointestinal infections.

The most defining feature of UC's course is the alternation between flares and periods of remission, which can last months or even years. The goal of treatment isn't a one-time resolution of symptoms, but achieving clinical and endoscopic remission and maintaining it for as long as possible — each subsequent flare raises the risk of complications, hospitalization, and eventually surgery.

How severe the symptoms are depends heavily on how much of the colon is inflamed. Inflammation limited to the rectum (proctitis) may cause mainly bleeding and urgency with a fairly normal bowel movement rhythm, while extensive inflammation covering the entire colon (pancolitis) usually involves frequent, watery, bloody diarrhea, significant pain, and systemic symptoms like fever or tachycardia during severe flares.

A UC diagnosis is never based on a single test — it's always a combination of the clinical picture, lab results, and endoscopic and histopathological findings. The core test is colonoscopy with biopsies taken from various parts of the colon, which allows assessment of the continuity and extent of inflammatory changes and rules out other causes, including Crohn's disease, infectious colitis, or microscopic colitis.

Among lab tests, fecal calprotectin — a protein released by neutrophils — is the most useful in everyday practice; its elevated level correlates with active inflammation of the intestinal lining and helps distinguish UC from functional bowel disorders like irritable bowel syndrome without repeating a colonoscopy at every check-up. Standard blood tests (CBC, CRP, ferritin) help assess the degree of anemia and inflammation, but on their own neither confirm nor rule out the diagnosis.

The foundation of treatment for mild to moderate UC, both for inducing and maintaining remission, remains 5-aminosalicylates (5-ASA), primarily mesalamine, given orally, rectally (suppositories, enemas), or as a combination of both. The choice of formulation depends on the extent of disease — in inflammation limited to the rectum, topical treatment tends to work better than oral treatment alone.

5-ASA drugs are generally well tolerated, and their long-term safety profile is favorable, making them the only drug class in this disease suited to years-long maintenance therapy without a meaningful rise in complication risk. They don't work for every patient, though — when they fail to achieve or maintain remission, moving to the next step of the treatment ladder becomes necessary.

In severe flares requiring hospitalization, IV steroids are used, and failure to respond within 3 days signals the need for urgent treatment intensification — including rescue therapy with infliximab or cyclosporine, or, when drug treatment fails, colectomy. A severe UC flare is a condition that, in the hospital, requires close monitoring, since it can progress quickly to life-threatening complications.

For patients with moderate to severe disease who don't respond to 5-ASA or who are steroid-dependent, biologic drugs have become the standard — anti-TNF antibodies (infliximab, adalimumab, golimumab), the anti-integrin antibody vedolizumab, which acts selectively on the gut, and newer anti-IL-23 drugs (e.g., ustekinumab, mirikizumab). Added to these are oral small-molecule JAK inhibitors (tofacitinib, upadacitinib), which also have documented efficacy for inducing and maintaining remission in this group of patients.

Choosing a specific biologic depends on many individual factors — prior exposure to other biologics, coexisting conditions, patient preference regarding the route of administration (IV, subcutaneous, oral), and a safety profile relevant to that particular case. It's a decision made jointly with a gastroenterologist, often at a center specializing in inflammatory bowel disease, not one a patient should make on their own based on general descriptions found online.

Chronic bleeding and inflammation predispose UC patients to iron deficiency and anemia, which is why periodic checks of CBC and ferritin are an important part of care — we cover how to interpret those results in our separate article on iron. Some patients, especially after longer periods of diarrhea or during certain medication courses, also use probiotic supplements to support the gut microbiome, though the evidence for their effectiveness in treating UC itself remains mixed and strain-dependent.

Beyond acute flare complications, long-standing, extensive UC carries an increased risk of colorectal cancer that rises with disease duration and extent. That's why patients with UC extending beyond the rectum alone should be enrolled in a regular surveillance colonoscopy program, usually starting 8-10 years after diagnosis — the exact schedule is set by the treating gastroenterologist based on individual risk.

UC is a disease where the most is gained on two fronts: sticking to the treatment ladder set jointly with a gastroenterologist instead of looking for alternatives to replace treatment, and staying alert to warning signs that shouldn't wait for the next scheduled visit. Nutritional or supplemental support, including the curcumin we cover separately, has its place as an add-on to therapy — but it's the regular use of 5-ASA, or escalated treatment when needed, that really determines how long and how good the remission is.